Artivion, Inc. (NYSE:AORT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $49.1143.

AORT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Needham & Company LLC upped their price objective on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. Finally, JMP Securities boosted their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th.

Insider Buying and Selling at Artivion

In other news, CEO James P. Mackin sold 34,210 shares of the firm’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $45.86, for a total value of $1,568,870.60. Following the transaction, the chief executive officer owned 800,993 shares of the company’s stock, valued at approximately $36,733,538.98. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Marshall S. Stanton sold 47,376 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the sale, the senior vice president directly owned 44,753 shares of the company’s stock, valued at approximately $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 234,511 shares of company stock valued at $10,612,452. 8.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artivion

Several large investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth about $27,000. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. State of Wyoming bought a new stake in shares of Artivion in the third quarter worth about $80,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Artivion in the third quarter worth about $92,000. Institutional investors own 86.37% of the company’s stock.

Artivion Price Performance

Artivion stock opened at $44.27 on Monday. The business’s fifty day moving average is $45.70 and its two-hundred day moving average is $41.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The firm has a market cap of $2.10 billion, a P/E ratio of -184.47 and a beta of 1.59. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The firm’s revenue for the quarter was up 18.9% on a year-over-year basis. Equities research analysts forecast that Artivion will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.